While this suggests angiogenesis markers could aid early detection, clinical trials of VEGF inhibitors such as sorafenib—alone or combined with gemcitabine—failed to improve outcomes in advanced pancreatic cancer (6). This evidence concerns the gene VEGFA and familial pancreatic carcinoma.